A new study has been published in the Official Journal of the World Federation of Haemophilia on patient with haemophilia preferences between prophylactic factor replacement therapy (PFRT) and gene therapy. The study is based on the Patient preferences to Assess Value IN Gene therapies (PAVING) survey conducted in Belgium and reveals that preferences for gene therapy in haemophilia are heterogenous and mainly influenced by patient’s comprehension and education on novel therapies